Windlas Biotech
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Windlas Biotech's management has articulated a disciplined approach to growth, emphasizing long-term performance through strategic capacity expansion and operational efficiency. The upcoming Plant 6 is expected to enhance production capabilities, positioning the company to capitalize on volume-led growth in the CDMO and Exports segments. Despite facing temporary setbacks in the Trade Generics segment, management is optimistic about bridging these gaps through geographic and portfolio diversification. Vista's financial outlook reflects a moderation in revenue growth, aligning with management's cautious yet strategic expansion plans. The stable margin expectations are supported by improving pricing power within the industry, although ongoing API price volatility remains a concern. The broader industry context, characterized by a growing demand for CDMO services and favorable regulatory changes, further supports Windlas's growth trajectory. Over the next 12-24 months, key opportunities include leveraging the expansion of the Jan Aushadhi Kendra network and capturing market share from patent expirations. However, watchpoints include potential regulatory challenges and rising operational costs that could impact profitability
Why We Like This Stock
- Strategic capacity expansion with the upcoming Plant 6 is expected to enhance production capabilities
- Strong operational performance and a net debt-free balance sheet provide a solid foundation for growth
- Favorable industry dynamics, including improving pricing power and demand for CDMO services, support revenue potential
Things To Watch Out For
- Temporary setbacks in the Trade Generics segment due to the discontinuation of codeine-based products may impact short-term revenue
- Ongoing API price volatility and rising operational costs pose risks to margin stability
- Regulatory compliance challenges could hinder operational efficiency and market competitiveness
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 631 | 760 | 904 | 946 | 1,080 |
| Profit Before Tax (Cr.) | 77 | 79 | 87 | 90 | 103 |
| PBT Margin | 12.2% | 10.4% | 9.6% | 9.5% | 9.6% |
| Net Profit (Cr.) | 60 | 62 | 66 | 69 | 79 |
| Earnings Per Share | 28.8 | 29.8 | 32.0 | 33.2 | 38.0 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. The company sells generic medicines, health supplements, and custom-branded formulations under Windlas brand names. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.